One of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs for blood cancers. While these therapies have shown great promise for some indications, we still lack effective therapies for many others. A novel route to address this is to the restore innate immunity’s ability to fight cancer.
Lessons learned in the face of new health challenges
BackgroundSARS-COV-2 exposed our vulnerability and strategic weakness at European level, in terms of biotechnological manufacturing capacity.
Novo Holdings invests into standardisation of LC-MS-based proteomics
Latest NewsEvosep APS has inked a $40m funding deal with Novo Holdings A/S that is aimed to advance standardised clinical LC-MS-based drug discovery and diagnostic multi-marker tests.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
Latest NewsWith the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
Latest NewsRational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks €15m deal with Indian Ciplas
Latest NewsCipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
First hints for leukopenia diagnostic in MS
Latest NewsScientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
Collaboration to develop mRNA vaccine against betacoronaviruses
Latest NewsCEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.
First allogeneic cancer immunotherapy hits market
Latest NewsAtara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.
Innate immunity and its power in cancer therapy
BackgroundOne of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs for blood cancers. While these therapies have shown great promise for some indications, we still lack effective therapies for many others. A novel route to address this is to the restore innate immunity’s ability to fight cancer.
Numares AG cashes in €20m from EIB
Latest NewsThe European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.